Extracapsular cataract extraction and posterior chamber intraocular lens implantation in uveitis patients

Ophthalmology. 1992 Aug;99(8):1234-41. doi: 10.1016/s0161-6420(92)31818-4.

Abstract

Purpose: Intraocular lens implantation in uveitis patients has been a controversial issue. The purpose of this study is to evaluate the visual and surgical outcomes of extracapsular cataract extraction (ECCE) and posterior chamber intraocular lens (PC IOL) implantation in a diverse group of uveitis patients.

Patients and methods: The results of 39 cases of ECCE and PC IOL implantation in 30 patients with uveitis were retrospectively analyzed. Five patients (six eyes) had pars plana vitrectomies combined with ECCE and PC IOL implantation. Patient age ranged from 26 to 71 years (average, 53.0 years). Specific uveitic syndromes were determined for 22 patients (73.3%). The postoperative follow-up period ranged from 6 to 43 months (average, 20.3 months).

Results: Visual acuity improved postoperatively in 38 eyes (97.4%), and this improvement ranged from 1 to 11 Snellen lines (average, 7.5 Snellen lines). Visual acuity improved postoperatively to 20/40 or better in 32 eyes (82%). Seven eyes had visual acuity worse than 20/40, which was attributed to posterior segment abnormalities after ECCE and PC IOL implantation. Uveitis recurred in 20 eyes (51.3%), and postoperative cystoid macular edema (CME) was observed in 18 eyes (46.2%). In all cases, the recurrent uveitis and CME improved or resolved with corticosteroid therapy.

Conclusion: These results suggest selected uveitis patients can have improved vision without unacceptable risk for 1 to 3 years after ECCE and PC IOL implantation.

MeSH terms

  • Adult
  • Aged
  • Cataract Extraction*
  • Female
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use
  • Humans
  • Lenses, Intraocular*
  • Male
  • Middle Aged
  • Postoperative Complications
  • Recurrence
  • Retrospective Studies
  • Treatment Outcome
  • Uveitis / drug therapy
  • Uveitis / etiology
  • Uveitis / surgery*
  • Visual Acuity

Substances

  • Glucocorticoids